Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.